Get the Stockscreener App
17.54
2.07%
0.355
Trevi Therapeutics Inc stock is traded at $17.54, with a volume of 1.65M.
It is up +2.07% in the last 24 hours and up +0.09% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
See More
Previous Close:
$17.18
Open:
$17.36
24h Volume:
1.65M
Relative Volume:
0.81
Market Cap:
$2.49B
Revenue:
-
Net Income/Loss:
$-45.61M
P/E Ratio:
-54.20
EPS:
-0.3235
Net Cash Flow:
$-45.40M
1W Performance:
-8.05%
1M Performance:
+0.09%
6M Performance:
+75.53%
1Y Performance:
+123.66%
1-Day Range:
$16.92
$17.54
1-Week Range:
$16.62
$19.37
52-Week Range:
$6.55
$20.22
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
17.54 | 2.49B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
TRVI|Trevi Therapeutics Inc|Price:17.535|Chg%:+0.355 - TradingKey
Affinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Siren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Fifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - The Manila Times
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
TRVI Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $24 - Moomoo
BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target - marketscreener.com
BMO initiates Trevi Therapeutics stock at Outperform, $36 target By Investing.com - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1%Here's Why - MarketBeat
TRVI Maintains Buy by B. Riley Securities -- Price Target Raised to $31.00 - GuruFocus
B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
TRVI Maintains Buy Rating -- Price Target Raised to $24.00 by HC Wainwright - GuruFocus
B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating - marketscreener.com
HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - GuruFocus
Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright - Investing.com Canada
Trevi Therapeutics (TRVI) Is Up 6.9% After Haduvio Cough Data And New ILD Trial PlanHas The Bull Case Changed? - webull.com
TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum - timothysykes.com
TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers - timothysykes.com
TRVI Jumps As Trevi Therapeutics Extends Rally On Heavy Interest - StocksToTrade
Trevi Therapeutics Stock Jumps As Momentum Traders Pile In - timothysykes.com
TRVI Jumps As Trevi Therapeutics Extends Bullish Run - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year HighHere's Why - MarketBeat
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market - Yahoo Finance
Why Trevi Therapeutics (TRVI) Stock Is Up Today - Moomoo
Trevi climbs as GSK drops chronic cough therapy (TRVI:NASDAQ) - Seeking Alpha
TRVI Stock Firms Up As Haduvio Story Hits Center Stage - StocksToTrade
Trevi Therapeutics (TRVI) Sees Significant Price Increase - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference - International Business Times Australia
Stock Traders Buy Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.4%What's Next? - MarketBeat
Candriam S.C.A. Purchases Shares of 773,620 Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (TRVI) Slips 3% as Shares Approach Key Support at $16.95Earnings Quality Factor - dars.gov.et
Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial - TipRanks
Trevi Therapeutics Inc. (TRVI) Q1 2026 Earnings: EPS Miss and No Revenue Highlight the Challenges of a Pre-Commercial BiotechEarnings Expansion Phase - DonanımHaber
SG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
TRVi stock stays tied to Trevi Therapeutics' clinical outlook - AD HOC NEWS
Price to earnings forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to sales forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to book forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Enterprise value to revenue forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to earnings forward of Trevi Therapeutics, Inc. – BOATS:TRVI - TradingView
Trevi Therapeutics stock hits all-time high at 19.33 USD By Investing.com - Investing.com South Africa
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):